OREXIGEN THERAPEUTICS INC's ticker is and the CUSIP is 686164AC8. A total of 7 filers reported holding OREXIGEN THERAPEUTICS INC in Q1 2017. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $2,550,000,000 | -15.0% | 7,500,000 | 0.0% | 0.04% | +2.3% |
| Q3 2017 | $3,000,000,000 | 0.0% | 7,500,000 | 0.0% | 0.04% | -10.2% |
| Q2 2017 | $3,000,000,000 | 0.0% | 7,500,000 | 0.0% | 0.05% | -3.9% |
| Q1 2017 | $3,000,000,000 | – | 7,500,000 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Telemetry Investments, L.L.C. | 9,401,000 | $4,883,000 | 2.19% |
| SILVERBACK ASSET MANAGEMENT LLC | 4,800,000 | $2,424,000 | 0.60% |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 9,500,000 | $4,981,000 | 0.07% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 7,500,000 | $3,000,000,000 | 0.05% |
| Orbimed Advisors | 5,210,000 | $2,591,000 | 0.03% |
| Daiwa Securities Group Inc. | 2,578,000 | $1,276,000 | 0.01% |
| Citadel Advisors | 3,000,000 | $1,463,000 | 0.00% |